Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Editors in Chief

Daniel R. Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD, has disclosed that he has received consulting fees from Gilead Sciences and ViiV and fees for non-CME/CE services from Gilead Sciences. Dr. Kuritzkes in previous editions has disclosed that he has received consulting fees from Bristol-Myers Squibb, Celera, GlaxoSmithKline, InnaVirVax, Merck, and Tobira and funds for contracted research from Merck.

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
Associate Director, Clinical and Translational Research Center
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb, GlaxoSmithKline/ViiV, and Tobira; has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, Kainos, Koronis, Merck, Tibotec/Janssen, and Tobira; and has served on the data safety and monitoring board for Vertex. Dr. Eron disclosed in previous editions that he had received consulting fees from Avexa, Chimerix, Inhibitex, Myriad, Pfizer, and Virco; had received funds for research support from Merck, Panacos, TaiMed, and Tobira; and had served on speaker bureaus for Bristol-Myers Squibb, Gilead Sciences, Roche, Tibotec, and Virco.

Section Editor

Joel E. Gallant, MD, MPH

Medical Director of Specialty Services
Southwest CARE Center
Santa Fe, New Mexico
Adjunct Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Joel E. Gallant, MD, MPH, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Merck, Janssen, and ViiV and funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck, Janssen, Sangamo, and ViiV. Dr. Gallant disclosed in previous editions that he had received funds for research support from Gilead Sciences, Roche, and Vertex; had served as a consultant for Abbott, Japan Tobacco, and Takara Bio; had received honoraria from Monogram Biosciences; had served on advisory boards for Pfizer, RAPID Pharmaceuticals, Tibotec, and ViiV; and had served on data and safety monitoring boards for Gilead Sciences, Koronis, and Sangamo.

Authors

Marshall J. Glesby, MD, PhD

Associate Professor of Medicine
Director, Cornell Clinical Trials Unit
Weill Cornell Medical College
New York, New York

Marshall J. Glesby, MD, PhD, has no real or apparent conflicts of interest to report. Dr. Glesby disclosed in previous editions that he had received funds for research support from Pfizer and served as a consultant for Gilead Sciences and Pfizer.

Timothy J. Wilkin, MD, MPH

Associate Professor of Medicine
Co-Director, Cornell Clinical Trials Unit
Weill Cornell Medical College
New York, New York

Timothy J. Wilkin, MD, MPH, has disclosed that he has received funds for research support from Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline/ViiV; has served as a consultant for GlaxoSmithKline and ViiV; and that his spouse is an employee of Johnson & Johnson. Dr. Wilkin disclosed in previous editions that he had received funds for research support from GlaxoSmithKline, Janssen, and Merck and served as a consultant for Merck, Pfizer, Quest Diagnostics, and Tibotec.

Staff

Edward King, MA

Executive Vice President

Edward King, MA, has no real or apparent conflicts of interest to report.

Heather Stieglitz, PhD

Editorial Contributor

Heather Stieglitz, PhD, has no real or apparent conflicts of interest to report.

Jennifer M. Blanchette, PhD

Managing Editor

Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.

Jenny Schulz, PhD

Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Sheralee Connors, MA

Editorial Contributor

Sheralee Connors, MA, has no real or apparent conflicts of interest to report.

Additional Disclosure Information

The following faculty and staff have previously contributed to the content of this module and disclosed the following potential conflicts of interest:

Kathleen E. Squires, MD, disclosed that she had served on advisory boards for scientific purposes for Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV; had served on advisory boards for marketing purposes for Gilead Sciences and Janssen; had served on advisory boards for Boehringer Ingelheim, GlaxoSmithKline, Koronis, Pfizer, Schering-Plough, Tobira, and Tibotec; had received funds for research support from BioCryst, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Koronis, Merck, Schering-Plough, Tibotec, and Vertex; and had received consulting fees from GlaxoSmithKline and Merck at the time she contributed to this module.

Kimberly Y. Smith, MD, MPH, disclosed that she had served on advisory boards and as a consultant for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Tibotec, and ViiV and had participated in speaker bureaus for GlaxoSmithKline and Merck at the time she contributed to this module.

Taryn O’Loughlin Gross, PhD; Elaine P. Seeskin; Melinda B. Tanzola, PhD; and John Delehanty, PhD, had no real or apparent conflicts of interest to report at the time they contributed to this module.

Disclaimer

The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Contact Information

If you have technical queries about using this site, please contact: techhelp@clinicaloptions.com.

If you have credit related queries or a complaint, please contact: skelley@clinicaloptions.com.

inPractice Hepatology current certification period
Release Date: March 2, 2020
Expiration Date: March 1, 2021

Target Audience

This program is intended for physicians and other healthcare professionals involved in the medical management of patients with or at risk of viral hepatitis.

Goal:

The goal of this activity is to improve learners’ knowledge and competence regarding the clinical management of patients with viral hepatitis.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

Commercial Support

This program is supported by educational grants from AbbVie.


inPractice HIV current certification period
Release Date: September 26, 2019
Expiration Date: September 25, 2020

Target Audience

This activity is intended for physicians and other healthcare professionals involved in the management of patients with HIV.

Goal:

The goal of this activity is to provide a comprehensive clinical reference resource on the prevention, diagnosis, and treatment of HIV disease.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

Commercial Support:

This program is supported by educational grants from Gilead Sciences and ViiV Healthcare.


For inPractice Hepatology and HIV

Physician Continuing Medical Education (for Point of Care CME activities)
CCO

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


CCO designates this internet point-of-care activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Credit (Point of Care CME)

inPractice offers physicians AMA PRA Category 1 CreditTM for participation in this individual Internet point-of-care activity. Physicians may claim 0.5 credits per search. To claim point-of-care (PoC) CME credit through inPractice, eligible physicians must complete the following steps:

  1. Register online at http://www.inpractice.com
  2. Execute a search or submit a clinical question
  3. Review the applicable clinical sources
  4. Click the "Claim CME Credit" button at the top right corner of the content you have viewed
  5. Complete the simple evaluation questions addressing clinical application of learnings from the sources you have consulted

After submitting the evaluation, you will be presented with your online CME certificate as a pdf file. Records of all CME activities completed can be found on the "My CME" page.